Poslední aktualizace :
19/11/2024
rakovina drog   Trastuzumab  
injekce
Stabilita roztoků Stabilita směsí Faktory ovlivňující stabilitu Kompatibilita Způsoby aplikace Odkazy pdf

Obchodní název   Obchodní název     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Herceptin äpanÏlsko, Argentina, Austrálie, Belgie, BrazÌlie, Chile, Dánsko, Egypt, Ekvádor, Finsko, Francie, Írán, Irsko, Island, Itálie, Japonsko, Kanada, Kolumbie, Lucembursko, Malajsie, MaÔarsko, Maroko, Mexiko, NÏmecko, Nizozemsko, Norsko, nový Zéland, Peru, Polsko, Portugalsko, Rakousko, Rumunsko, Saúdská Arábie, Spojené arabské emiráty, Švédsko, Švýcarsko, Turecko, USA, Velká Británie, ÿecko
Herclon Peru
Hertraz Chile
Herzuma äpanÏlsko, Belgie, Francie, NÏmecko, USA, Velká Británie
Kanjinti äpanÏlsko, Belgie, NÏmecko, Velká Británie
Trastuzumab Baxter nový Zéland
Trazimera Velká Británie
Odkazy   injekce   Odkazy : Trastuzumab  
typ uveřejnění
2296 Laboratoř Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
2975 plakát Nalenz H, Schoenhammer K, Dietel E, Heynen S.R, Grauschopf U, Mahler H.C.
In-Use stability of herceptin for subcutaneous injection with different administration materials.
ESCP 2014 2014
3077 Laboratoř Trastuzumab (Herceptin®) – Summary of Product Characteristics
Roche 2019
3113 kniha Herceptin
Compendium Suisse des m?dicaments 2010
3258 noviny Kaiser J, Krämer I.
Physicochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags.
Int J Pharm Compound 2011 ; 15, 6 : 515-520.
3343 plakát Vieillard V, da Silva R, Astier A, Paul M.
Physicochemical stability of diluted trastuzumab solutions stored 6 months at 4°C.
ECOP Congress, Budapest, Hungary 2012
3366 noviny Kwong Glover Z.W, Gennaro L, Yadav S, Demeule B, Wong P.Y, Sreedhara A.
Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration.
J Pharm Sci 2012 ; DOI 10.1002 / jps.23403
3386 noviny Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier A.
Long-term physico-chemical stability of diluted trastuzumab.
Int J Pharm 2013 ; 448: 101-104.
3647 Laboratoř Trastuzumab (Herceptin® 600 mg for subcutaneous injection) - Summary of Product Characteristics
Roche 2019
3849 noviny Pabari R.M, Ryan B, Ahmad W, Ramtoola Z.
Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions.
Curr Pharm Biotech 2013 ; 14, 2: 220-225.
4163 noviny Nalenz H, K?pf E, Dietel E.
Prolonged In-Use Stability of Reconstituted Herceptin in Commercial Intravenous Bags.
Int J Pharm Compound 2018 22;5:417-423
4191 noviny Vieillard V, Astier A, Paul M.
Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at varioustemperatures.
GaBI Journal 2018
4194 noviny Kim S.J, Lee J.W, Kang H.Y, Kim S.Y, Shin Y.K, Kim K.W, Oh J.S, Lim K.J, Kim J.Y.
In-Use Physichochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion.
Bio Drugs 2018 32;619-625
4271 noviny Yun J, Kim J, Chung J, Hwang S-J, Park S-J.
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Adv Ther 2019
4396 noviny Lueras A, Polozova A, Asbury D, Hippenmeyer J, Litowski J, Goss M, Breslin P, Crampton S.
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions.
GaBI Journal 2020 ; 9, 1:
4477 noviny Crampton S, Polozoxa A, Asbury D, Lueras A, Breslin P, Hippenmeyer J, Litkowski J,,Goss M.
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentration and stress conditions.
GaBI Journal 2020 ; 9, 1: 5-13.
4493 noviny Le Guyader G, Vieillard V, Paul M.
Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
J Oncol Pharm Practice 2020
4649 noviny Davies L, Milligan K, Corris M, Clarke I, Dwyer P, Lee S-E, Teraoka J, Crouse-Zeineddini J, Hippenmeyer J.
Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices.
GaBI Journal 2021 ; 10, 4
4754 noviny Weiser S, Burns C, Zartler E
Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions.
J Oncol Pharm Practice 2023 ;29,3:

  Mentions Légales